The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

The company said the patient, an African American-Asian woman diagnosed with lupus nephritis, received fludarabine-free ...

Aurinia Pharmaceuticals (AUPH) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall ...

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...

Fate Therapeutics (NASDAQ:FATE) stock rallied 37% Monday after the company reported that the first patient in the Phase 1 ...

There are multiple chapters near you. Select your preferred chapter.

Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical ...